Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02867306
Recruitment Status : Completed
First Posted : August 15, 2016
Last Update Posted : March 15, 2019
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:

The primary purpose of the study is to evaluate the effect of ASP1707 twice daily on the pharmacokinetics of once weekly oral methotrexate (MTX).

This study will also evaluate the effect of MTX on multiple-dose pharmacokinetics of ASP1707, as well as safety and tolerability of coadministration of ASP1707 and MTX in patients with rheumatoid arthritis (RA).


Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: ASP1707 Drug: methotrexate (MTX) Phase 1

Detailed Description:
Patients will check into the clinic on Day -1 and remain in the clinic until all exit procedures have been performed on the morning of Day 10.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-label, Single-sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis
Actual Study Start Date : July 25, 2016
Actual Primary Completion Date : August 30, 2016
Actual Study Completion Date : August 30, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ASP1707 and methotrexate (MTX)
On day 1 patients will receive prescribed dose of MTX. On Days 3 through 8, patients will receive ASP1707 (twice daily). On Day 9, patients will receive a single dose in the morning. A single dose of MTX will be coadministered on Day 8.
Drug: ASP1707
Oral

Drug: methotrexate (MTX)
Oral




Primary Outcome Measures :
  1. Pharmacokinetics of methotrexate (MTX) in plasma: AUCinf [ Time Frame: Up to Day 8 ]
    Area under the concentration-time curve from the time of dosing extrapolated to time infinity (AUCinf)

  2. Pharmacokinetics of methotrexate (MTX) in plasma: Cmax [ Time Frame: Up to Day 8 ]
    Maximum concentration (Cmax)


Secondary Outcome Measures :
  1. Pharmacokinetics of methotrexate (MTX) in plasma: AUClast [ Time Frame: Up to Day 8 ]
    Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)

  2. Pharmacokinetics of methotrexate (MTX) in plasma: tmax [ Time Frame: Up to Day 8 ]
    Time after dosing when Cmax occurs (tmax)

  3. Pharmacokinetics of methotrexate (MTX) in plasma: t 1/2 [ Time Frame: Up to Day 8 ]
    Apparent terminal elimination half-life (t 1/2)

  4. Pharmacokinetics of methotrexate (MTX) in plasma: CL/F [ Time Frame: Up to Day 8 ]
    Apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)

  5. Pharmacokinetics of methotrexate (MTX) in plasma: Vz/F [ Time Frame: Up to Day 8 ]
    Apparent volume of distribution during the terminal elimination phase (Vz/F)

  6. Pharmacokinetics of 7-hydroxymethotrexate (7-OH-MTX) in plasma: AUClast [ Time Frame: Up to Day 8 ]
  7. Pharmacokinetics of 7-hydroxymethotrexate (7-OH-MTX) in plasma: tmax [ Time Frame: Up to Day 8 ]
  8. Pharmacokinetics of 7-hydroxymethotrexate (7-OH-MTX) in plasma: t 1/2 [ Time Frame: Up to Day 8 ]
  9. Pharmacokinetics of 7-hydroxymethotrexate (7-OH-MTX) in plasma: MPR [ Time Frame: Up to Day 8 ]
    Metabolite to parent ratio of AUC using AUC(corr) for the metabolite (corrected by molecular weight ratio of parent to metabolite) (MPR)

  10. Pharmacokinetics of methotrexate (MTX) in urine: Aelast [ Time Frame: Up to Day 8 ]
    Cumulative amount of analyte excreted into the urine up to the collection time of the last measurable concentration (Aelast)

  11. Pharmacokinetics of methotrexate (MTX) in urine: Aelast% [ Time Frame: Up to Day 8 ]
    Percent of drug dose excreted into urine, feces or bile (Aelast) from time of dosing up to the collection time of the last measurable concentration (Aelast%)

  12. Pharmacokinetics of methotrexate (MTX) in urine: CLR [ Time Frame: Up to Day 8 ]
    Renal clearance (CLR)

  13. Pharmacokinetics of 7-hydroxymethotrexate (7-OH-MTX) in urine: Aelast [ Time Frame: Up to Day 8 ]
  14. Pharmacokinetics of 7-hydroxymethotrexate (7-OH-MTX) in urine: Aelast% [ Time Frame: Up to Day 8 ]
  15. Pharmacokinetics of 7-hydroxymethotrexate (7-OH-MTX) in urine: CLR [ Time Frame: Up to Day 8 ]
  16. Pharmacokinetics of ASP1707 in plasma: AUCtau [ Time Frame: Up to Day 8 ]
    Area under the concentration-time curve from the time of dosing to the start of the next dosing interval (AUCtau)

  17. Pharmacokinetics of ASP1707 in plasma: Cmax [ Time Frame: Up to Day 8 ]
  18. Pharmacokinetics of ASP1707 in plasma: tmax [ Time Frame: Up to Day 8 ]
  19. Pharmacokinetics of ASP1707 in plasma: CL/F [ Time Frame: Up to Day 8 ]
  20. Pharmacokinetics of ASP1707 in plasma: Ctrough [ Time Frame: Up to Day 9 ]
    Concentration immediately prior to dosing at multiple dosing (Ctrough)

  21. Pharmacokinetics of ASP1707 in plasma: MPR [ Time Frame: Up to Day 8 ]
  22. Pharmacokinetics of AS1948006 in plasma: AUCtau [ Time Frame: Up to Day 8 ]
  23. Pharmacokinetics of AS1948006 in plasma: Cmax [ Time Frame: Up to Day 8 ]
  24. Pharmacokinetics of AS1948006 in plasma: tmax [ Time Frame: Up to Day 8 ]
  25. Pharmacokinetics of AS1948006 in plasma: Ctrough [ Time Frame: Up to Day 8 ]
  26. Pharmacokinetics of AS1948006 in plasma: MPR [ Time Frame: Up to Day 8 ]
  27. Safety as assessed by Adverse Events (AEs) [ Time Frame: Up to Day 13 ]
  28. Safety assessed by Laboratory Test: hematology [ Time Frame: Up to Day 13 ]
  29. Safety assessed by Laboratory Test: biochemistry [ Time Frame: Up to Day 13 ]
  30. Safety assessed by Laboratory Test: serology [ Time Frame: Up to Day 13 ]
  31. Safety assessed by Laboratory Test: urinalysis [ Time Frame: Up to Day 13 ]
  32. Safety assessed by 12- lead electrocardiogram (ECG) [ Time Frame: Up to Day 10 ]
    All ECGs should be recorded using the clinic's calibrated equipment. This overall conclusion will be recorded as normal, abnormal not clinically significant, or abnormal clinically significant.

  33. Number of participants with Physical Examination abnormalities and/or adverse events [ Time Frame: Up to Day 10 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patient must either:

    • Be of nonchildbearing potential: postmenopausal (defined as at least 2 years after last regular menstrual cycle) prior to screening and follicle-stimulating hormone (FSH) ≥ 30 IU/mL, or
    • documented surgically sterile
  • Or, if of childbearing potential,

    • Agree not to try to become pregnant during the study and for 28 days or 5 half-lives, whichever is longer, after the final study drug administration;
    • and have a negative urine pregnancy test at screening;
    • and, if heterosexually active, agree to consistently use 2 forms of highly effective birth control (at least one of which must be a barrier method) starting at screening and throughout the study period and for 28 days or 5 half-lives, whichever is longer, after the final study drug administration.
  • Male patient and his female spouse/partner who is of childbearing potential must be using highly effective forms of contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the study period and for 60 days after the final study drug administration.
  • Female patient must agree not to breastfeed starting at screening and throughout the study period, and for 28 days or 5 half-lives, whichever is longer, after the final study drug administration.
  • Female patient must not donate ova starting at screening and throughout the study period, and for 28 days or 5 half-lives, whichever is longer, after the final study drug administration.
  • Male patient must not donate sperm starting at screening and throughout the study period, and for 60 days after the final study drug administration.
  • Patient agrees not to participate in another interventional study while on treatment.
  • Patient has a body mass index (BMI) of ≤ 35 kg/m2, inclusive, and must weigh at least 50 kg at screening.
  • Patient must have a clinical diagnosis of RA according to the 2010 criteria of the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) at least 6 months prior to screening.
  • Patient meets the ACR 1991 revised criteria for RA Global Functional Status I or II.
  • Patient must be on concomitant MTX at a stable 10 to 25 mg/week dose for ≥ 28 days prior to day 1 and throughout the study.
  • Patient on other medications (excluding MTX) for the treatment or RA at the time of screening must be able to discontinue these medications 28 days or 5 half-lives (whichever is longer) before first study drug dose:

    o Hydroxychloroquine, cyclosporine, leflunomide and sulfasalazine

  • Patient use of nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, folic acid, low dose opioids, hormone replacement therapy (HRT), corticosteroids (prednisone equivalent of ≤ 5 mg/day) for treatment of RA may be allowed in the study. These medications must be stable for ≥ 28 days prior to screening and patients should remain on their regimen throughout the study. Occasional acetaminophen use (less than 2 g/day) may be allowed.
  • Patient use of conventional and biologic disease-modifying antirheumatic drugs (DMARDs) used to treat RA may be allowed in this study. These medications must be stable for 4 weeks prior to the study and remain stable during the study. Prior approval for its use must be obtained from the sponsor.

Exclusion Criteria:

  • Patient has a previous history of clinically significant systemic disease which might confound the results of the study or pose an additional risk in administering study drug(s) to the patient. This may include, but not be limited to, a history of drug or food allergies, uncompensated heart failure, uncontrolled diabetes mellitus, severe hepatic failure, severe pulmonary disease, or history of mental disease.
  • Patient has a history of any malignancy in the past 5 years, except for adequately-treated nonmelanoma skin cancer and adequately-treated-in-situ cervical cancer.
  • Patient has a positive serology test for hepatitis B surface antigen (HbsAg) or hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) 1+2 antibodies.
  • Patient received any breast cancer resistance protein (BCRP) transporter inhibitors or substrates, with the exception of MTX, within 28 days or 5 half-lives, whichever is longer, prior to day 1.
  • Patient with liver enzyme test abnormalities, aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin > 2 times the upper limit of normal (ULN).
  • Patient has a recent history (within the last 6 months) of drug or alcohol abuse (as defined by the Investigator) or a positive urine screen for alcohol or drugs of abuse/illegal drugs at screening or check-in.
  • Patient has participated in a previous clinical study with treatment with ASP1707.
  • Patient has received any investigational agent within 28 days or 5 half-lives, whichever is longer, prior to day 1.
  • Patient has had any significant blood loss, donated 1 unit (450 mL) of blood, or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to day 1.
  • Patient is an employee of the Astellas group or vendors involved with the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02867306


Locations
Layout table for location information
Moldova, Republic of
Site MD37301
Chisinau, Moldova, Republic of, MD-2025
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Investigators
Layout table for investigator information
Study Director: Senior Medical Director Astellas Pharma Global Development, Inc. (APGD)

Additional Information:
Layout table for additonal information
Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT02867306     History of Changes
Other Study ID Numbers: 1707-CL-3002
2016-001192-76 ( EudraCT Number )
First Posted: August 15, 2016    Key Record Dates
Last Update Posted: March 15, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
methotrexate (MTX)
Pharmacokinetics
ASP1707
Rheumatoid Arthritis (RA)

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors